AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Veru Inc (NASDAQ:VERU)
0.627 USD
-0.028 4.319%Sponsored Reports
Loading...
| Previous Close (in USD) | 0.6553 |
|---|---|
| Change | -0.028 4.319% |
| 52 W H/L (in USD) | 1.920/0.360 |
| EBITDA (in USD) | -46.047M |
| PE Ratio | -- |
| Volume | 854966 |
| Diluted Eps TTM | -0.35 |
| Total Assets (in USD) | 50.596M |
|---|---|
| Total Liabilities (in USD) | 32.813M |
| Revenue TTM (in USD) | 13.479M |
| Cash (in USD) | 9.625M |
| Market Cap (in USD) | 174.197 M |
| Revenue Per Share TTM | 0.127 |
| Gross Profit TTM (in USD) | 30.591M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Veru Inc
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Employees: 189
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Mitchell S. Steiner F.A.C.S, F.A.C.S., M.D. | Chairman, Pres & CEO | 1961 |
| 2. | Dr. Harry Fisch F.A.C.S., M.D. | Vice Chairman & Chief Corp. Officer | 1959 |
| 3. | Ms. Michele Greco | CFO & Chief Admin. Officer | 1959 |
| 4. | Dr. K. Gary Barnette Ph.D. | Chief Scientific Officer | 1968 |
| 5. | Mr. Samuel Fisch | Exec. Director of Investor Relations & Corp. Communications | NA |
| 6. | Mr. Michael J. Purvis | Exec. VP, Gen. Counsel & Corp. Strategy and Sec. | NA |
| 7. | Mr. Kevin J. Gilbert CPA, J.D. | Exec. VP of Corp. Devel. | NA |
| 8. | Dr. Domingo Rodriguez M.D. | Exec. VP of Global Clinical Operations | 1962 |
| 9. | Dr. Gary Bird Ph.D. | Exec. VP of Quality & Regulatory Affairs | NA |
| 10. | Mr. Joel Batten | Exec. VP & GM of Infectious Disease Franchise | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.070 1.581% | 68.76 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+2.420 3.640% | 68.9 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+2.740 0.618% | 442.99 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.606 0.500% | 521.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 30-09-2023 | 30-09-2022 | 30-09-2021 | 30-09-2020 | 30-09-2019 |
|---|---|---|---|---|---|
| Income Before Tax | -92.609M | -83.54M | 4.265M | -20.052M | -12.321M |
| Minority Interest | - | - | - | - | - |
| Net Income | -93.089M | -83.776M | 7.394M | -18.974M | -12.017M |
| Selling General Administrative | 48.058M | 43.169M | 20.67M | 14.498M | 14.349M |
| Gross Profit | 7.566M | 30.591M | 47.927M | 30.787M | 21.657M |
| Reconciled Depreciation | 0.27M | 0.21M | 0.211M | 0.463M | 0.471M |
| Ebit | -94.968M | -83.433M | -5.438M | -15.209M | -6.907M |
| Ebitda | -94.698M | -83.224M | -23.848M | -14.747M | -6.436M |
| Depreciation And Amortization | 0.27M | 0.21M | -18.41M | 0.463M | 0.471M |
| Operating Income | -93.718M | -83.224M | -5.438M | -14.747M | -6.436M |
| Other Operating Expenses | 111.839M | 122.578M | 66.697M | 57.339M | 38.239M |
| Interest Expense | 2.427M | 4.369M | 4.852M | 4.621M | 4.706M |
| Tax Provision | 0.48M | 0.236M | -3.129M | -1.078M | -0.304M |
| Interest Income | - | - | - | - | 5.885M |
| Net Interest Income | -2.427M | -4.369M | -4.886M | -4.621M | -4.706M |
| Income Tax Expense | 0.48M | 0.236M | -3.129M | -1.078M | -0.304M |
| Total Revenue | 16.297M | 39.354M | 61.26M | 42.592M | 31.803M |
| Total Operating Expenses | 103.108M | 113.815M | 53.365M | 45.534M | 28.093M |
| Cost Of Revenue | 8.731M | 8.763M | 13.332M | 11.805M | 10.147M |
| Total Other Income Expense Net | 5.36M | -0.316M | 9.703M | -5.305M | -5.885M |
| Net Income From Continuing Ops | -93.089M | -83.776M | 7.394M | -18.974M | -12.017M |
| Net Income Applicable To Common Shares | - | -83.776M | 7.394M | -18.974M | -12.017M |
Balance Sheet
(Currency in USD)| Breakdown | 30-09-2023 | 30-09-2022 | 30-09-2021 | 30-09-2020 | 30-09-2019 |
|---|---|---|---|---|---|
| Total Assets | 50.596M | 136.126M | 178.147M | 51.544M | 53.629M |
| Intangible Assets | 0.006M | 3.977M | 4.049M | 5.752M | 20.168M |
| Other Current Assets | 1.098M | 12.409M | 15.025M | 1.495M | 1.843M |
| Total Liab | 32.813M | 55.287M | 25.853M | 21.432M | 21.296M |
| Total Stockholder Equity | 17.783M | 80.839M | 152.294M | 30.111M | 32.333M |
| Other Current Liab | 4.665M | 18.265M | 9.12M | 1.1M | 5.51M |
| Common Stock | 0.94M | 0.827M | 0.822M | 0.72M | 0.672M |
| Capital Stock | 0.94M | 0.827M | 0.822M | 0.72M | 0.672M |
| Retained Earnings | -258.663M | -165.574M | -81.798M | -89.193M | -70.219M |
| Good Will | 6.879M | 6.879M | 6.879M | 6.879M | 6.879M |
| Other Assets | - | 14.528M | 13.903M | 10.233M | 9.423M |
| Cash | 9.625M | 80.191M | 122.36M | 13.589M | 6.295M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 20.279M | 41.438M | 15.767M | 14.727M | 14.02M |
| Current Deferred Revenue | -0.865M | - | - | 3.285M | - |
| Net Debt | 4.78M | -65.271M | -109.725M | 0.548M | 5.822M |
| Short Term Debt | 1.901M | 1.169M | 3.237M | 7.529M | 5.386M |
| Short Long Term Debt | 0.865M | 1.169M | 3.237M | 5.842M | 5.386M |
| Short Long Term Debt Total | 14.405M | 14.919M | 12.634M | 14.136M | 12.118M |
| Other Stockholder Equity | 276.088M | 246.167M | 233.852M | 119.165M | 102.461M |
| Property Plant Equipment | - | 5.973M | 0.593M | 0.313M | 0.352M |
| Total Current Assets | 23.506M | 104.769M | 151.753M | 27.015M | 16.807M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 4.507M | 3.551M | 8.794M | 5.227M | 5.021M |
| Long Term Debt | 8.87M | 9.656M | 9.397M | 5.617M | 2.886M |
| Inventory | 6.697M | 8.619M | 5.574M | 6.704M | 3.647M |
| Accounts Payable | 14.577M | 22.003M | 3.41M | 2.813M | 3.125M |
| Accumulated Other Comprehensive Income | -0.582M | -0.582M | -0.582M | -0.582M | -0.582M |
| Non Currrent Assets Other | 1.512M | 1.562M | 2.441M | 0.766M | 0.989M |
| Non Current Assets Total | 27.09M | 31.357M | 26.393M | 24.529M | 36.822M |
| Capital Lease Obligations | 4.671M | 5.051M | 1.108M | 1.577M | - |
| Long Term Debt Total | - | - | - | - | 2.886M |
Cash Flow
(Currency in USD)| Breakdown | 30-09-2023 | 30-09-2022 | 30-09-2021 | 30-09-2020 | 30-09-2019 |
|---|---|---|---|---|---|
| Investments | 6.334M | 4.267M | 14.623M | -0.106M | -0.109M |
| Total Cashflows From Investing Activities | - | 4.267M | 14.623M | -0.106M | -0.109M |
| Total Cash From Financing Activities | 11.114M | 1.069M | 109.718M | 9.329M | 8.129M |
| Net Income | -93.089M | -83.776M | 7.394M | -18.974M | -12.017M |
| Change In Cash | -70.565M | -42.169M | 108.771M | 7.294M | 2.536M |
| Begin Period Cash Flow | 80.191M | 122.36M | 13.589M | 6.295M | 3.76M |
| End Period Cash Flow | 9.625M | 80.191M | 122.36M | 13.589M | 6.295M |
| Total Cash From Operating Activities | -88.014M | -47.505M | -15.571M | -1.93M | -5.485M |
| Depreciation | 0.27M | 0.21M | 0.211M | 0.463M | 0.471M |
| Other Cashflows From Investing Activities | - | 4.267M | 15M | -0.106M | -0.106M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | 0.649M | -3.127M | 0.546M | -3.302M | -1.454M |
| Sale Purchase Of Stock | - | 1.078M | 109.738M | -0.05M | 13.333M |
| Other Cashflows From Financing Activities | 5.105M | 1.078M | 1.638M | 13.815M | 3.665M |
| Capital Expenditures | 0.666M | 0.733M | 0.377M | 0.106M | 0.109M |
| Change In Working Capital | -15.215M | 25.882M | -7.283M | -4.346M | -1.564M |
| Other Non Cash Items | 1.924M | -1.139M | -17.376M | 19.536M | 6.157M |
| Free Cash Flow | -88.68M | -48.238M | -15.948M | -2.036M | -5.594M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 3889604 |
| 2. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 858412 |
| 3. | Fidelity Extended Market Index | 1 year ago | 716861 |
| 4. | iShares Micro-Cap ETF | 1 year ago | 285428 |
| 5. | Fidelity Total Market Index | 1 year ago | 163483 |
| 6. | NT Ext Equity Mkt Idx Fd - NL | 1 year ago | 145079 |
| 7. | BlackRock Extended Mkt Composite | 1 year ago | 114883 |
| 8. | NT Ext Equity Mkt Idx Fd - L | 1 year ago | 109357 |
| 9. | Northern Trust Extended Eq Market Idx | 1 year ago | 109357 |
| 10. | BlackRock Extended Equity Market K | 1 year ago | 100262 |
| 11. | Fidelity Series Total Market Index | 1 year ago | 97909 |
| 12. | Vanguard Balanced Index Inv | 1 year ago | 82146 |
| 13. | Fidelity Nasdaq Composite Index | 1 year ago | 69064 |
| 14. | T. Rowe Price U.S. Equities Tr | 1 year ago | 63300 |
| 15. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 1 year ago | 62459 |
| 16. | Spartan Extended Market Index Pool E | 1 year ago | 62048 |
| 17. | Vanguard U.S. Eq Idx £ Acc | 1 year ago | 58213 |
| 18. | Vanguard Instl Ttl Stk Mkt Idx InstlPls | 1 year ago | 33254 |
| 19. | Vanguard Instl Ttl Stck Mkt Idx Tr | 1 year ago | 33254 |
| 20. | FT TOP Picks July 2022 CA | 1 year ago | 29476 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Adage Capital Partners Gp LLC | 1 year ago | 11022222 |
| 2. | Perceptive Advisors LLC | 1 year ago | 5584699 |
| 3. | Vanguard Group Inc | 1 year ago | 4717908 |
| 4. | Rosalind Advisors, Inc. | 1 year ago | 4500000 |
| 5. | Octagon Capital Advisors LP | 1 year ago | 3800000 |
| 6. | AIGH Capital Management, LLC | 1 year ago | 3438551 |
| 7. | Morgan Stanley - Brokerage Accounts | 1 year ago | 2730119 |
| 8. | MAVEN SECURITIES Ltd | 1 year ago | 2385853 |
| 9. | Altium Capital Management, LP | 1 year ago | 2000000 |
| 10. | LAURION CAPITAL MANAGEMENT LP | 1 year ago | 1700000 |
| 11. | J. Goldman & Co LP | 1 year ago | 1380451 |
| 12. | BlackRock Inc | 1 year ago | 1173445 |
| 13. | Millennium Management LLC | 1 year ago | 1131723 |
| 14. | Ikarian Capital, LLC | 1 year ago | 946382 |
| 15. | Worth Venture Partners, LLC | 1 year ago | 855855 |
| 16. | Alpine Partners VI, LLC | 1 year ago | 710000 |
| 17. | Geode Capital Management, LLC | 1 year ago | 662250 |
| 18. | Potomac Capital Management, Inc. | 1 year ago | 654000 |
| 19. | ADAR1 Capital Management LLC | 1 year ago | 500000 |
| 20. | Blair William & Co | 1 year ago | 330000 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...